The Trump administration is currently considering implementing a five-year pilot program that would provide coverage for weight-loss drugs under Medicare and Medicaid, according to the Washington Post.
The report is based on documents from the Centers for Medicare and Medicaid Services that describe the proposal.
The drugs under consideration for coverage include Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly’s Zepbound and Mounjaro, the documents showed.
Â
Click this link for the original source of this article.
Author: Ray Hilbrich
This content is courtesy of, and owned and copyrighted by, https://www.offthepress.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
